 
                                                    Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases.
Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis.
Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.4M | 
| Three Month Average Volume | 37.9M | 
| High Low | |
| Fifty-Two Week High | 32.59 USD | 
| Fifty-Two Week Low | 14.55 USD | 
| Fifty-Two Week High Date | 22 Dec 2023 | 
| Fifty-Two Week Low Date | 10 Jun 2024 | 
| Price and Volume | |
| Current Price | 16.58 USD | 
| Beta | 0 | 
| Relative Price Change | |
| Four Week Relative Price Change | -16.39% | 
| Thirteen Week Relative Price Change | 2.59% | 
| Twenty-Six Week Relative Price Change | -37.20% | 
| Fifty-Two Week Relative Price Change | -51.03% | 
| Year-to-Date Relative Price Change | -55.28% | 
| Price Change | |
| One Day Price Change | 1.59% | 
| Thirteen Week Price Change | 9.80% | 
| Twenty-Six Week Price Change | -30.95% | 
| Five Day Price Change | 4.02% | 
| Fifty-Two Week Price Change | -38.64% | 
| Year-to-Date Price Change | -47.05% | 
| Month-to-Date Price Change | -12.83% | 
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.62226 USD | 
| Book Value Per Share (Most Recent Quarter) | 3.1154 USD | 
| Tangible Book Value Per Share (Last Fiscal Year) | 2.2245 USD | 
| Tangible Book Value Per Share (Most Recent Quarter) | 2.46508 USD | 
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 0.20714 USD | 
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 4.43439 USD | 
| Revenue Per Share (Trailing Twelve Months) | 5.38215 USD | 
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD | 
| Dividend Per Share (Trailing Twelve Months) | 0 USD | 
| Dividend Per Share (5 Year) | -99999.99 USD | 
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.37411 USD | 
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.18131 USD | 
| Normalized (Last Fiscal Year) | -0.37411 USD | 
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.37411 USD | 
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.18316 USD | 
| Including Extraordinary Items (Last Fiscal Year) | -0.37411 USD | 
| Including Extraordinary Items (Trailing Twelve Months) | 0.18131 USD | 
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.66544 USD | 
| Cash Per Share (Most Recent Quarter) | 3.02039 USD | 
| Cash Flow Per Share (Last Fiscal Year) | -0.33997 USD | 
| Cash Flow Per Share (Trailing Twelve Months) | 0.25398 USD | 
| Free Cash Flow Per Share (Trailing Twelve Months) | 0.48638 USD | 
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -22 | 
| Cash Flow Revenue (Trailing Twelve Months) | 9 | 
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 5.14% | 
| Pretax Margin (Last Fiscal Year) | -7.03% | 
| Pretax Margin (5 Year) | -37.76% | 
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 94.27% | 
| Gross Margin (Trailing Twelve Months) | 91.72% | 
| Gross Margin (5 Year) | 95.62% | 
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -10.10% | 
| Operating Margin (Trailing Twelve Months) | 2.56% | 
| Operating Margin (5 Year) | -39.88% | 
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -8.44% | 
| Net Profit Margin (Trailing Twelve Months) | 3.43% | 
| Net Profit Margin (5 Year) | -38.35% | 
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -4.67% | 
| Tangible Book Value (5 Year) | -5.07% | 
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% | 
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 46.44% | 
| Revenue Growth (3 Year) | 26.55% | 
| Revenue Change (Trailing Twelve Months) | 61.65% | 
| Revenue Per Share Growth | 20.19% | 
| Revenue Growth (5 Year) | 18.03% | 
| Capital Spending Debt | |
| Capital Spending (5 Year) | 79.52% | 
| Total Debt (5 Year) | -99,999.99% | 
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% | 
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 2,876.74% | 
| EPS Change (Trailing Twelve Months) | 126.51% | 
| EPS Growth (3 Year) | -99,999.99% | 
| EPS Growth (5 Year) | -99,999.99% | 
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% | 
| EBITDA (5 Year Interim) | -99,999.99% | 
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% | 
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 8 | 
| Price to Tangible Book (Most Recent Quarter) | 7 | 
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 | 
| Price to Free Cash Per Share (Trailing Twelve Months) | 34 | 
| Net Debt | |
| Net Debt (Most Recent Quarter) | -500,942,000 | 
| Net Debt (Last Fiscal Year) | -438,865,000 | 
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 4 | 
| Price to Sales (Trailing Twelve Months) | 3 | 
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 91 | 
| PE Normalized (Last Fiscal Year) | -100,000 | 
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 89 | 
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 90 | 
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 90 | 
| PE Including Extraordinary Items (Trailing Twelve Months) | 91 | 
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% | 
| Dividend Yield | -99,999.99% | 
| Current Dividend Yield | 0.00% | 
| Price to Book | |
| Price to Book (Last Fiscal Year) | 6 | 
| Price to Book (Most Recent Quarter) | 5 | 
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 | 
| Long Term Debt to Equity (Most Recent Quarter) | 0 | 
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% | 
| Payout Ratio (Trailing Twelve Months) | 0.00% | 
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 | 
| Quick Ratio (Most Recent Quarter) | 2 | 
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 | 
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 54 | 
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 | 
| Current Ratio (Most Recent Quarter) | 2 | 
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,348,000 | 
| Free Cash Flow (Trailing Twelve Months) | 80.5M | 
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 | 
| Net Interest Coverage (Trailing Twelve Months) | -100,000 | 
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 | 
| Total Debt to Equity (Most Recent Quarter) | 0 | 
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -9.17% | 
| Return on Assets (Trailing Twelve Months) | 3.93% | 
| Return on Assets (5 Year) | -27.50% | 
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -14.73% | 
| Return on Equity (Trailing Twelve Months) | 6.70% | 
| Return on Equity (5 Year) | -35.33% | 
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -12.81% | 
| Return on Investment (Trailing Twelve Months) | 5.93% | 
| Return on Investment (5 Year) | -32.73% |